Fibroblast growth factor receptor 4 (FGFR4): A targetable regulator of drug resistance in colorectal cancer

Cell Death and Disease

Volumn 5, Issue 2, 2014, Pages

  Turkington, R C ^a   Longley, D B ^a   Allen, W L ^a   Stevenson, L ^a   McLaughlin, K ^a   Dunne, P D ^a   Blayney, J K ^a   Salto Tellez, M ^a   Van Schaeybroeck, S ^a   Johnston, P G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

5 fluorouracil; colorectal; drug resistance; FGFR4; oxaliplatin

Indexed keywords

BGJ 398; CASPASE; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FIRTECAN; FLICE INHIBITORY PROTEIN; FLUOROURACIL; OXALIPLATIN; RECEPTOR BLOCKING AGENT; STAT3 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; DRUG TARGETING; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; PHENYLUREA COMPOUNDS; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; STAT3 TRANSCRIPTION FACTOR;

EID: 84896778773     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.10     Document Type: Article

References (48)

1. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005; 205 275-292.
2. Stevenson L, Allen WL, Turkington R, Jithesh PV, Proutski I, Stewart GE et al. Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer. Clin Cancer Res. 2012; 18 5412-5426.
3. Turner N, Grose R. Fibroblast growth factor signalling: From development to cancer. Nat Rev 2010; 10: 116-129.
4. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006; 281: 15694-15700.
5. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996; 271: 15292-15297.
6. Wu X, Ge H, Lemon B, Weiszmann J, Gupte J, Hawkins N et al. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc Natl Acad Sci USA. 2009; 106: 14379-14384.
7. Wu X, Ge H, Lemon B, Vonderfecht S, Weiszmann J, Hecht R et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 2010; 285-5170.
8. Gowardhan B, Douglas DA, Mathers ME, McKie AB, McCracken SR, Robson CN et al. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 2005; 92: 320-327.
9. Penault-Llorca F, Bertucci F, Adelaide J, Parc P, Coulier F, Jacquemier J et al. Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer 1995; 61: 170-176.
10. Shah RN, Ibbitt JC, Alitalo K, Hurst HC. FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1alpha. Oncogene 2002; 21: 8251-8261.
11. Lin BC, Wang M, Blackmore C, Desnoyers LR. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 2007; 282: 27277-27284.
12. Jaakkola S, Salmikangas P, Nylund S, Partanen J, Armstrong E, Pyrhonen S et al. Amplification of fgfr4 gene in human breast and gynecological cancers. Int J Cancer 1993 378-382.
13. Leung HY, Gullick WJ, Lemoine NR. Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int J Cancer 1994; 59: 667-675.
14. Olson DC, Deng C, Hanahan D. Fibroblast growth factor receptor 4, implicated in progression of islet cell carcinogenesis by its expression profile, does not contribute functionally. Cell Growth Differ 1998; 9: 557-564.
15. Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, Gnanapragasam VJ. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 2007; 213: 82-90.
16. Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 2002; 109: 69-78.
17. Nicholes K, Guillet S, Tomlinson E, Hillan K, Wright B, Frantz GD et al. A mouse model of hepatocellular carcinoma: Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002; 160: 2295-2307.
18. French DM, Lin BC, Wang M, Adams C, Shek T, Hotzel K et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One 2012; 7: E36713.
19. Roidl A, Foo P, Wong W, Mann C, Bechtold S, Berger HJ et al. The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells. Oncogene 2010; 29: 1543-1552.
20. Taylor JGt, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K et al. Identification of FGFR4-Activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 2009; 119: 3395-3407.
21. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002; 62: 840-847.
22. Wang J, Stockton DW, Ittmann M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 2004 (18 Pt 1): 6169-6178.
23. Streit S, Mestel DS, Schmidt M, Ullrich A, Berking C. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer 2006; 94: 1879-1886.
24. da Costa Andrade VC, Parise Jr. O, Hors CP, de Melo Martins PC, Silva AP, Garicochea B. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 2007; 82: 53-57.
25. Liu R, Li J, Xie K, Zhang T, Lei Y, Chen Y et al. FGFR4 promotes stroma-induced epithelialto-mesenchymal transition in colorectal cancer. Cancer Res 2013; 73: 5926-5935.
26. Desnoyers LR, Pai R, Ferrando RE, Hotzel K, Le T, Ross J et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008; 27: 85-97.
27. Roidl A, Berger HJ, Kumar S, Bange J, Knyazev P, Ullrich A. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res 2009 15 2058-2066.
28. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1- yl)-phenylamin o]-pyrimidin-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 2011; 54: 7066-7083.
29. Wilson TR, McEwan M, McLaughlin K, Le Clorennec C, Allen WL, Fennell DA et al. Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells. Oncogene 2009; 28: 63-72.
30. Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006; 25 848.
31. Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD et al. Characterization of p53 wild-Type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 2004; 10: 2158-2167.
32. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B et al. Colorectal cancer. Lancet 2010; 375: 1030-1047.
33. Longley DB, Allen WL, Johnston PG. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta 2006; 1766: 184-196.
34. Ong SH, Guy GR, Hadari YR, Laks S, Gotoh N, Schlessinger J et al. FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors. Mol Cell Biol 2000; 20: 979-989.
35. Mohammadi M, Honegger AM, Rotin D, Fischer R, Bellot F, Li W et al. A tyrosinephosphorylated carboxy-Terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol Cell Biol 1991; 11 5078.
36. Li C, Chen L, Iwata T, Kitagawa M, Fu XY, Deng CX. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum Mol Genet 1999; 8: 35-44.
37. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000; 19: 3309-3320.
38. Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC et al. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer Res 2012; 18: 3780-3790.
39. Tateno T, Asa SL, Zheng L, Mayr T, Ullrich A, Ezzat S. The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis. PLoS Genet 2011; 7: E1002400.
40. Chioni AM, Grose R. FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior. J Cell Biol 2012; 197: 801-817.
41. Adam RM, Danciu T, McLellan DL, Borer JG, Lin J, Zurakowski D et al. A nuclear form of the heparin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma. Cancer Res 2003; 63: 484-490.
42. Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, Hung MC. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 2005; 65 348.
43. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009; 28: 3801-3813.
44. Xia W, Wei Y, Du Y, Liu J, Chang B, Yu YL et al. Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog 2009; 48: 610-617.
45. Allen WL, Stevenson L, Coyle VM, Jithesh PV, Proutski I, Carson G et al. A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer. Mol Cancer Ther 2012; 11: 119-131.
46. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
47. Wilson TR, McLaughlin KM, McEwan M, Sakai H, Rogers KM, Redmond KM et al. c-FLIP: A key regulator of colorectal cancer cell death. Cancer Res 2007; 67: 5754-5762.
48. Oladipo O, Conlon S, O'Grady A, Purcell C, Wilson C, Maxwell PJ et al. The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue. Br J Cancer 2011; 104: 480-487.